SCIEX Builds on Cadence of Innovation in Biopharma With Biologics Explorer

New application software enables protein characterization analysis for the ZenoTOF 7600 system

SCIEX , a global leader in life science analytical technologies and Danaher operating company, launches Biologics Explorer software, enabling customers to acquire insights from their high-resolution protein characterization data, and reach decisions quickly and confidently on the most important critical quality attributes for biopharmaceuticals. Biologics Explorer signifies the next step in innovation, building upon the ZenoTOF 7600 system , alongside Molecule Profiler .

To bring life-saving protein therapeutics to market safely and rapidly, it is critical to fully characterize candidate molecules at every stage of development. Biologics Explorer allows scientists to harness the full potential of the incredibly rich spectra produced from the Zeno trap and electron activated dissociation (EAD), from the ZenoTOF 7600 system, into highly informative and actionable results. These results are based upon a nodal algorithm structure that enables each processing and analysis step to be optimized so scientists can get the clear answers they need from their assays.

"The launch of the ZenoTOF 7600 system is the beginning of new possibilities for biopharmaceutical scientists and sets the pace for a cadence of innovation," said Mani Krishnan, VP GM, CE & Biopharma at SCIEX. "While Molecule Profiler extended the ZenoTOF 7600 system's capabilities into oligonucleotides, Biologics Explorer extends the reach once more, this time into protein therapeutics. Together, the ZenoTOF 7600 system with these new software applications will provide fresh and deeper insights for biologic manufacturers, allowing them to rapidly progress their therapies through the pipeline."

The strategic software partnership between SCIEX and Genedata allows for this expansion of functionality. Biologics Explorer is built upon Genedata Expressionist®, industry-leading enterprise software platform for biopharmaceutical mass spectrometry.

"I am delighted to see the value delivered by our software platform as an out-of-the-box desktop solution addressing the specific needs of SCIEX customers. Partnerships like this help to deliver new capabilities to the wider biopharma community and enable the opportunity for an enterprise implementation with Genedata Expressionist where required," said Othmar Pfannes, Ph.D., CEO of Genedata.

Currently available workflows include intact and subunit analysis, PTM determination and MAM, peptide mapping by EAD or CID and disulfide bond analysis.

To learn more about the Biologics Explorer and other software offerings, visit here .

About SCIEX

SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have led the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.

Today, as part of the Danaher (NYSE: DHR) family of global science and technology innovators, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.

That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, visit sciex.com .

Let's connect: Twitter , LinkedIn , Facebook , and Instagram .

Advances in human wellness depend on the power of precise science.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics . All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks ).

© 2021 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-13757-A.

Lulu VanZandt
Manager, Brand, Public Relations and Social Media, SCIEX
lulu.vanzandt@sciex.com
+1 (508) 383-7163
M: +1 (508) 782-9484

News Provided by Business Wire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×